JosephRosenthalMD

Director, Pediatric Hematology/Oncology

Dr. Rosenthal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
1500 Duarte Rd
Duarte, CA 91010
Phone+1 626-359-8111

Fax+1 626-408-3911

University of California (Irvine)/Children's Hospital of Orange CountyFellowship, Pediatric Hematology/Oncology, 1993 - 1996
University of ColoradoFellowship, Pediatric Hematology/Oncology, 1988 - 1991
Tel Aviv University SacklerClass of 1983

PubMed

485 citations
Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease
John E. Wagner, Joseph Rosenthal, Robert Sweetman, Xiao-Ou Shu, Stella M. Davies
Blood. 1996-08-01
53 citations
Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease
Francisco Lopez, Pablo Parker, Auayporn Nademanee, Roberto Rodriguez, Zaid S Al-Kadhimi
Biology of Blood and Marrow Transplantation. 2005-04-01
35 citations
Unrelated Donor Bone Marrow Transplantation for Children With Acute Myeloid Leukemia Beyond First Remission or Refractory to Chemotherapy
Nancy Bunin, Stella M. Davies, Richard Aplenc, Bruce M. Camitta, Kenneth B. DeSantes
Journal of Clinical Oncology. 2008-09-10

Abstracts/Posters

Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World E...
Joseph Rosenthal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Life-Changing Transplant Gives Sickle Cell Patient a Second ChanceOctober 3rd, 2018
$City of Hope Certified to Provide First FDA-Approved CAR T Cell Therapy for Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia$
City of Hope Certified to Provide First FDA-Approved CAR T Cell Therapy for Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic LeukemiaApril 13th, 2018
Promising Sickle Cell Research Gets Nearly $6MM Boost from CIRMMarch 22nd, 2018
Join now to see all